Benefits of Testosterone Replacement Therapy in Hypogonadal Males.

Hypogonadal men receiving TRT had a lower 3-year mortality rate compared to those not receiving TRT.

• Mortality rate was 3.1% in the TRT group versus 3.6% in the no-TRT group.
• Relative risk was 0.886 (P < .001).
• Study used propensity-matched retrospective EMR data from 57 healthcare organizations between 2005 and 2020.
• Cohort consisted of males aged 40 to 80 years diagnosed with hypogonadism.

Hypogonadal men receiving TRT had a decreased risk of atrial fibrillation compared to those not receiving TRT.

• AF rate was 3.6% in the TRT group versus 4.0% in the no-TRT group.
• Relative risk was 0.900 (P < .001).
• Outcome was measured over a 3-year follow-up period.
• Analysis was performed on propensity-matched cohorts from the TriNetX database.

Hypogonadal men receiving TRT had a lower rate of stroke compared to those not receiving TRT.

• Stroke rate was 1.6% in the TRT group versus 1.8% in the no-TRT group.
• Relative risk was 0.898 (P < .011).
• Outcome was measured over a 3-year follow-up period.
• The authors noted potential for missed cases of stroke not captured by the database.

Hypogonadal men receiving TRT had fewer cases of prostate cancer compared to those not receiving TRT.

• Prostate cancer rate was 1.9% in the TRT group versus 2.9% in the no-TRT group.
• Relative risk was 0.648 (P < .001), representing the largest relative risk reduction among all outcomes studied.
• Outcome was measured over a 3-year follow-up period.
• The authors noted potential for missed cases of prostate cancer not captured by the database.

No statistically significant difference in myocardial infarction rates between TRT and no-TRT groups was reported as a notable finding.

• MI was one of the pre-specified 3-year outcomes analyzed alongside mortality, AF, stroke, and prostate cancer.
• MI was not listed among the outcomes showing significant benefit in the abstract's results summary, unlike mortality, AF, stroke, and prostate cancer.
• The study included 163,456 male patients identified with hypogonadism, of whom 133,584 were included after propensity matching.
• Propensity matching was performed to reduce bias and balance confounding factors between the two groups.

The study utilized the TriNetX database with propensity matching to compare outcomes in hypogonadal men on TRT versus no TRT.

• Deidentified, retrospective EMR data from 57 participating healthcare organizations between 2005 and 2020 were used.
• Cohorts included males aged 40 to 80 years diagnosed with hypogonadism.
• 163,456 male patients were identified with hypogonadism; 133,584 were included after propensity matching.
• Propensity matching was performed to reduce bias and balance confounding factors between the two groups.